Our Technology
Our Team
Partnering
News
Contact Us
NEWS & RESEARCH
Filter:
Press Releases
Research Papers
News Articles
Presentations
RP
Research Papers
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations
30 August 2022
Read more
RP
Research Papers
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
5 July 2022
Read more
RP
Research Papers
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
1 January 2022
Read more
P
Presentations
Kurome CEO, Jan Rosenbaum, to Be a Featured Speaker at the Next Generation Kinase Inhibitors Summit
24 February 2022
Read more
P
Presentations
CCHMC Grand Rounds Presented by Jan Rosenbaum and Dan Starczynowski
15 February 2022
Read more
PR
Press Releases
Kurome Therapeutics: Rosenbaum’s Leadership Journey To Potentially Deliver Life-Saving Cancer Treatment
1 October 2021
Read more
PR
Press Releases
Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers
10 June 2021
Read more
RP
Research Papers
Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets
10 February 2021
Read more
NA
News Articles
TechOhio: This Cincinnati Startup is Innovating Targeted Cancer Treatments
26 January 2021
Read more
PR
Press Releases
Kurome Therapeutics launched to develop therapies targeting cancer's ability to evade treatment
29 April 2020
Read more
NA
News Articles
P&G alum tapped as CEO of Cincinnati Children’s spin-out company
29 April 2020
Cincinnati Business Courier
Read more
RP
Research Papers
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
Jones LM et al - 2020
Journal of Clinical Investigation
Read more
RP
Research Papers
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Melgar K et al – 2019
Science Translational Medicine
Read more
RP
Research Papers
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
Smith MA et al – 2019
Nature Cell Biology
Read more
RP
Research Papers
Chronic immune response dysregulation in MDS pathogenesis.
Barreyro L et al – 2018
Blood
Read more
RP
Research Papers
IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK et al - 2015
Oncotarget
Read more
RP
Research Papers
IRAK signalling in cancer
Rhyasen GW and Starczynowski DT – 2015
British Journal of Cancer
Read more
RP
Research Papers
IRAK1: Oncotarget in MDS and AML
Beverly LJ and Starczynowski DT - 2014
Oncotarget
Read more
RP
Research Papers
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome
Rhyasen GW et al – 2013
Cancer Cell
Read more
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.